We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Serological Markers of RA Determined in Patients with aβ2GPI-IgA

By LabMedica International staff writers
Posted on 14 Jun 2022
Print article
Image: The gold standard for the determination of antinuclear antibodies (ANA) is the indirect immunofluorescence test (IIFT) with human epithelial cells (HEp-2), which is known for its high sensitivity and specificity (Photo courtesy of Euroimmun)
Image: The gold standard for the determination of antinuclear antibodies (ANA) is the indirect immunofluorescence test (IIFT) with human epithelial cells (HEp-2), which is known for its high sensitivity and specificity (Photo courtesy of Euroimmun)

Rheumatoid arthritis (RA) is a chronic and systemic autoimmune disease. It is characterized by synovial inflammation that can lead to irreversible joint damage and disability when not managed. Biomarkers of RA available for routine clinical use are rheumatoid factors (RF) and anti-cyclic citrullinated peptides (CCP-Ab).

Beta 2 Glycoprotein I (β2GPI) is a plasma protein and plays a key role in hemostasis, homeostasis, and immunity. Antibodies against β2GPI (aβ2GPI) have been associated with antiphospholipid syndrome (APS) pathogenicity. Common links between RA and APS have been reported. Glycosylation is implicated in the synthesis of highly pathogenic forms of antibodies to citrullinated proteins. Moreover, dysregulation of glycosylation could also generate antibodies of APS.

Immunologists at the Farhat-Hached University Hospital (Sousse, Tunisia) conducted a retrospective study that included sera of 67 patients with anti-β2 glycoprotein I antibodies (aβ2GPI) of IgA isotype. Ninety healthy blood donors (HBD) were used as a control group. The serum samples were evaluated for aCL-IgG, IgA, and IgM using a commercial enzyme-linked immunosorbent assay (ELISA; Orgentec Diagnostika, Mainz, Germany). Results were expressed as arbitrary units with a cutoff for positivity of 10 U/mL for IgA and IgG and 7 U/mL for IgM.

The determination of aβ2GPI IgG, IgA, and IgM was carried out with an Orgentec Diagnostika commercial ELISA, using a purified human β2GPI. The results were expressed as arbitrary units with a cutoff for positivity of 8 U/mL. Antinuclear antibodies screening was performed by the indirect immunofluorescence technique using human epithelial type 2 (HEp-2) as a substrate (Euroimmun, Hamburg, Germany). Detection of ANA at a dilution superior to or equal to 1:80 was considered a positive result.

The scientists reported that 17 patients and eight HBD had CCP-Ab and/or RF (25.4% versus 8.9%, odds ratio = 3.5). The frequency of CCP-Ab was significantly higher in patients than in healthy subjects (14.9% versus 3.3%). IgA isotype of RF was significantly higher in patients than in controls (7.5% versus 0%). In male patients, CCP-Ab and/or RF were more frequent than in healthy male subjects (37.5% versus 11.8%). In patients, no correlation was found between the levels of aβ2GPI-IgA and CCP-Ab. There was no correlation between the level aβ2GPI-IgA and the level of the isotypes of RF (IgG, IgA, and IgM).

The authors concluded that a high frequency of autoantibodies of RA in patients with aβ2GPI-IgA, suggesting that these patients could be at higher risk of developing RA. Following the clinical features and serological markers of these patients over the years could confirm this data. The study was published on June 6, 2022 in the Journal of Clinical Laboratory Analysis.

Related Links:
Farhat-Hached University Hospital
Orgentec Diagnostika 
Euroimmun 

Automated ELISA-IFA-BLOT Processor AP 22
Gold Supplier
Quality Control Material
Multichem U
New
Gold Supplier
Auto Urinary Sediment Analyzer
EH-2030
New
Gold Supplier
Human Chorionic Gonadotropin (hCG) Test
OSOM hCG Combo Test

Print article

Channels

Industry

view channel
Image: Fujirebio has acquired ADx NeuroSciences for 40 million Euros (Photo courtesy of Pexels)

Fujirebio Acquires ADx NeuroSciences to Speed Development of Neurodegenerative Diseases Diagnostic Tests

Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.